* If you want to update the article please login/register
At the time of press about two clinical trials of hormone replacement therapy that were suspended due to poor results, we investigated the cessation of hormone replacement therapy among British women by educational level, socioeconomic status, and cardiovascular risk factors. Between January 2002 and February 2003, a total of 1387 women aged 57 years reported their monthly HRT use between January 2002 and February 2003. Changes in the trends of HRT usage were first detected in June 2002 and then again in July 2002. Various groups of British women may have had a different effect on the immediate decrease in HRT use by various groups of women.
Source link: https://doi.org/10.2105/ajph.2005.071332
The associations of childhood socioeconomic assessments with HRT use were not related to adult SEP, behavioral risk factors, and physiological risk factors for heart disease. Because the connection between early life SEP and HRT is not fully explained by adult risk factors, adult risk factors are not fully explained, residual confounding may account for some of the disparities in observational studies and randomized controlled trials in this field.
Source link: https://doi.org/10.2105/ajph.94.12.2149
OBJECTIVES: This report found the prevalence and causes of hormone replacement therapy counseling. HRT counseling was present in 43 percent, according to a report by the University of Hanoi, a 43 percent prevalence of HRT counseling was 43 percent. Women were more likely to receive HRT advice if they were White, older, more qualified, had undergone a hysterectomy, suffered from menopause, had a hysterectomy, had suffered menopausal signs, and had a regular source of care.
Source link: https://doi.org/10.2105/ajph.89.10.1575
A mail survey revealed that a mail survey found that a mail poll found that hormonal replacement therapy for postmenopausal women by Los Angeles area gynecologists, both now and ten years ago. By 86 percent of gynecologists using estrogen mixed with cyclic progesterone acetate, and 47 percent for women without a uterus, the estrogen is combined with cyclic progestin therapy, typically 10 mg of medroxyprogesterone acetate. Although the most common monthly hormonal therapy regimen for estrogen/progestin therapy is estrogen for days 1-25 and progestin for days 16-25, there is a wide variety in prescribing strategies.
Source link: https://doi.org/10.2105/ajph.78.5.516
Millions of menopausal women are taking hormone supplements. In the absence of results from randomized trials, how much of the apparent beneficial effect on heart disease is due to the inclination of healthier women to use these medications is unknown. Unknown effects of estrogen therapy on the cardiovascular system of a progestin-treated woman are unknown, and this regimen may raise the risk of breast cancer. Alternative ways to improve cardiovascular and skeletal health that do not raise the risk of cancer are also available.
Source link: https://doi.org/10.2105/ajph.83.12.1670
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions